Back

Avineuro Pharmaceuticals, Inc.
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.

Avineuro Pharmaceuticals, Inc. announces beginning of Phase I clinical studies of AVN-211, potent small molecule for treatment of schizophrenia.

San Diego, CA – March 5th, 2009 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-211 into Phase II clinical trials in Q2 2009. Avineuro Pharmaceuticals, Inc. will present at the 9th International Conference – AD/PD 2009 – Prague, Czech Republic, March 11-15, 2009.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com

Back

Avineuro Pharmaceuticals, Inc. A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.

San Diego, CA – October 28th, 2008.
Avineuro Pharmaceuticals, Inc was founded in August 2008 and is headquartered in San Diego, CA. The company operates in a virtual mode through outsourcing of the discovery, development and clinical activities. Avineuro’s pipeline  consists of pre-clinical drug candidates for treatment of Alzheimer’s Disease, anxiety, depression, schizophrenia and obesity. In September 2008, Avineuro entered into an exclusive licensing agreement with ChemDiv Inc. for drug candidates for treatment of multiple neurological and psychiatric indications. These candidates were identified from ChemDiv’s discovery platform through screening of its proprietary chemical library against a panel of GPCRs implicated in the pathophysiology of Alzheimer disease.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com

Back

Avineuro appoints Michael Brownstein, M.D. to the Scientific Advisory Board

San Diego, CA – October 29th, 2008 – Avineuro Pharmaceuticals, Inc. is pleased to announce that it has appointed Michael Brownstein, M.D. to its Scientific Advisory Board, effective immediately.

Michael Brownstein, M.D., Ph.D. brings over thirty years of experience as a scientific leader in the fields of genetics, endocrinology, pharmacology and drug development. Dr. Brownstein earned his bachelor’s degree from Columbia University and completed his medical training at University of Chicago, where he received his M.D. and Ph.D. in pharmacology. Dr. Brownstein has held leadership positions at NIH as Chief of the Laboratory of Genetics, NIMH/NHGIR, where he led the Brain Molecular Anatomy Project and the Molecular Gene Collection Project. He subsequently directed the Functional Genomics Program at the Venter Institute. Dr. Brownstein serves on numerous scientific and policy advisory boards has authored more than 200 research publications, and has founded several successful companies. His contributions have been recognized with the Distinguished Service Award for Biomedical Research, the Arthur S. Flemming Award, and the E. Gelhorn Prize in Neurophysiology, among other honors.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com

Back

Avineuro advances drug candidate to clinical development for treatment of Alzheimer’s disease.

San Diego, CA – October 30th, 2008 – Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer’s disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009. Results of the studies will be presented at the 9th International Conference – AD/PD 2009 – Prague, Czech Republic, March 11-15, 2009.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com

Back

Avineuro appoints Cynthia A. Lemere, Ph.D. to the Scientific Advisory Board

San Diego, CA – October 31st, 2008 – Avineuro Pharmaceuticals, Inc. is pleased to announce that it has appointed Cynthia A. Lemere, Ph.D. to its Scientific Advisory Board, effective immediately.

Cynthia A. Lemere, Ph.D. is an internationally recognized neurologist who has dedicated her research to new approaches for the treatment and prevention of Alzheimer’s disease. She is currently Associate Professor of Neurology at Harvard Medical School and an Associate Neuroscientist at Brigham & Women’s Hospital in the Center for Neurologic Diseases. Dr. Lemere received her B.A. from Mount Holyoke College, her M.S. in Neurobiology from State University of New York at Albany, and her Ph.D. in Pathology from Boston University School of Medicine.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email:YLavrovsky@avineuro.com